Bone Therapeutics Cracks On With Allogeneic Cells For Spinal Fusion, Broken Bones
Executive Summary
2019 should see top-line clinical results for Bone Therapeutics' off-the-shelf cell therapy for spinal fusion procedures.
You may also be interested in...
Bone Has Tough Path Forward After Phase III Knee Osteoarthritis Fail
The company said the study of JTA-004 failed to meet its primary and key secondary endpoints, though a post-hoc analysis indicated activity in a patient subset.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.